ArticleDermatology (Basel, Switzerland)2023
External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort.
Article in Dermatology (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.
- European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Guideline
- Guidelines How to Integrate Surgery and Targeted Therapy with Biologics for the Treatment of Hidradenitis Suppurativa: Delphi Consensus Statements from an Italian Expert Panel.Dermatology (Basel, Switzerland) · 2024Guideline
- Oral Zinc Supplementation in Acne Vulgaris and Hidradenitis Suppurativa: An Updated Comprehensive Review.Nutrients · 2026Review
- Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Towards a Paradigm Shift in Delivering Hidradenitis Suppurativa Care: a Narrative Review.Dermatology and therapy · 2025Review
- Hidradenitis Suppurativa Tunnels: Unveiling a Unique Disease Entity.JID innovations : skin science from molecules to population health · 2025Review
- Hidradenitis suppurativa, from basic science to surgery and a new era of tailored targeted therapy: An expert opinion paper.Archives of dermatological research · 2025Review
- Comprehensive Approach for Microbial Isolation from Hidradenitis Suppurativa Tunnels.Journal of visualized experiments : JoVE · 2025Article
- A Study on the Synergistic Effects of Hip Capsule Nerve and Stellate Ganglion Block on Postoperative Rehabilitation Outcomes in Elderly Patients Following Total Hip Arthroplasty.Geriatric orthopaedic surgery & rehabilitation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 20 institutions in 12 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreviously, a new dichotomous outcome was developed, calculated as 55% reduction in the International Hidradenitis Suppurativa 4 (IHS4-55) score. It was validated in datasets of adalimumab and placebo-treated HS patients. External validation is an important aspect of clinical outcomes.
objectivesWe aimed to externally validate the novel dichotomous IHS4-55 in a non-biologic treated dataset of HS patients.
methodsData from a previously published European-wide prospective clinical study of antibiotic treatment of HS patients were used to assess the association of IHS4-55 achievement with individual reduction in inflammatory nodules, abscesses, and draining tunnels. Moreover, the associations between IHS4-55 positivity and achievement of the minimal clinically important differences (MCIDs) for Dermatology Life Quality Index (DLQI), Numerical Rating Scale (NRS) Pain, and NRS Pruritus were analyzed.
resultsData were obtained from 283 individual patients, of which 36.4% (103/283) were treated with clindamycin and rifampicin and 63.6% (180/283) with tetracyclines for 12 weeks. Achievers of the IHS4-55 demonstrated a significant reduction the counts of inflammatory nodules, abscesses, and draining tunnels (all p < 0.001). Additionally, IHS4-55 achievers had an odds ratio for achieving the MCID of DLQI, NRS Pain, and NRS Pruritus of 2.16 (95% CI 1.28-3.65, p < 0.01), 1.79 (95% CI 1.10-2.91, p < 0.05), and 1.95 (95% CI 1.18-3.22, p < 0.01), respectively.
conclusionsThis study shows the external validity of the novel IHS4-55 by demonstrating a significant association between IHS4-55 achievement and a reduction in inflammatory lesion counts as well as achievement of MCIDs for DLQI, NRS Pain, and NRS Pruritus in an antibiotic-treated cohort. These findings support the use of the IHS4-55 as a novel primary outcome measure in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.